Trial Profile
Observational Retrospective Multicenter Study Aimed at Evaluating the Incidence of Hepatitis B Reactivation in Patients Affected by Chronic Lymphocytic Leukemia Treated With Ibrutinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 May 2022
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Lamivudine
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 11 May 2022 Status changed from recruiting to completed.
- 05 Oct 2020 Planned End Date changed from 1 Aug 2020 to 1 Jan 2021.
- 05 Oct 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Jan 2021.